Navigation Links
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
Date:4/22/2013

nd fractured a hip; death was attributed to renal failure and pulmonary sepsis.

"I am thrilled by the data from this Phase 2 study of VP20621, which confirm the therapeutic potential of non-toxigenic C. difficile," commented Dale Gerding , MD, Professor of Medicine at Loyola University Chicago Stritch School of Medicine and research physician at the Hines VA Hospital. "For the first time, we have been able to mimic the protective effect we have inferred from observing natural colonization of patients with non-toxigenic strains of C. difficile. As a clinician on the front lines of CDI research, I find these data to be extremely promising and suggestive of a novel approach to prevention of not only disease recurrence, but primary CDI as well."

Next steps
ViroPharma will complete the evaluation of these Phase 2 data which will help determine a future development pathway. The company reminds its investors that VP20621 was flagged as a non core asset at its September investor event. With these compelling Phase 2 clinical results, we will seek a partner to complete the development and commercialization of the asset.

About VP20621
Antibiotics including those used to treat acute C. difficile infection (CDI) disrupt the normal gastrointestinal flora which renders individuals susceptible to C. difficile colonization. Orally-dosed liquid VP20621 utilizes non-toxigenic spore-based technology as a potential means of recolonization and protection. The goal of VP20621 dosing following antibiotic exposure is to colonize with this non-toxigenic strain of C. difficile and to prevent colonization by toxigenic strains, thereby preventing disease. VP20621 may have therapeutic utility in the prevention of recurrence following treatment of acute CDI and in the primary prevention of CDI. ViroPharma acquired VP20621 in 2006, through a licensing agreement with Dr.
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)...  Sutro Biopharma today announced that it has ... president of alliance and project management. Dr. Vasquez ... of Sutro,s collaborative partnerships and the development of ... antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... of experience in the biopharmaceutical sector with expertise ...
(Date:8/4/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a specialty ... an emphasis on the treatment of primary and metastatic ... studies in Europe and the ... Delivery System (CHEMOSAT) will be presented at the upcoming ... be held in Marseille, France , ...
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics ... over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, announced ... of its ActiPatch 7-day trial device has been ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More ... survey and submitted an assessment.  ...
Breaking Medicine Technology:Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2
... DIEGO, Oct. 7 The West Wireless Health ... to Alan Viars, of Videntity, at the Health ... and open source platforms to enable people to ... networks as they work towards achieving health and ...
... 7 VentiRx Pharmaceuticals, Inc., a biopharmaceutical company ... 8 (TLR8) candidates for the treatment of cancer, ... its randomized, placebo controlled clinical trial evaluating VTX-1463 ... demonstrated that VTX-1463 significantly improved allergy symptoms based ...
Cached Medicine Technology:West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 2West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 3VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2
(Date:8/4/2015)... ... ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp in a ... have a flip-up face shield. The sleek contours of the new Nightstick NSP-4614B ... their headlamp when raising or lowering their face shield or visor. The 4614 will ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... the United States, Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors ... and will save lives," Dr. Carmona said. "I strongly believe in the mission ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Food,” scheduled for Nov. 3 – 4, 2015, at UC San Diego, will ... new businesses, improve food access, and manage resources efficiently against the dueling backdrop ...
(Date:8/4/2015)... ... August 04, 2015 , ... Many men are confused about the safety of ... standing up as a voice of authority for men seeking accurate information about testosterone. ... special experience and expertise in the safe and effective treatment of low testosterone. In ...
(Date:8/4/2015)... ... 04, 2015 , ... They say a picture is worth a thousand words, ... medical art can be essential. StayWell, a health solutions company, announced today it will ... have been used by physicians and other health care providers for more than 40 ...
Breaking Medicine News(10 mins):Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3
... , TUESDAY, Oct. 25 (HealthDay News) -- Teens who don,t ... boys, in particular, may be at risk for obesity, new research ... female students at a Texas high school and found that the ... males and 6 hours 30 minutes for females. The average sleep ...
... USA - In a report on a preclinical investigation ... Anti-caries DNA Vaccine," lead author Wei Shi, Wuhan Institute ... of researchers demonstrate that anti-caries DNA vaccines, including pGJA-P/VAX, ... because of the low immunogenicity of DNA vaccines. This ...
... COLUMBIA, Mo. -- Parkway School District in Chesterfield, Mo., ... came to suicide prevention. With a minimal amount of ... next steps should be after a tragic incident had ... MU College of Education,s Missouri Partnership for Educational Renewal ...
... American women of childbearing age suffer from chronic pelvic ... to endometriosis, a puzzling condition where cells that normally ... begin to colonize other organs and tissues beyond ... laparoscopic surgeons explores endometriosis from both the patient,s and ...
... -- Men who drink plenty of low-sugar fluids may ... Although the reason for the association between ... theorize the fluids may flush out potential cancer-causing agents ... In conducting the study, Jiachen Zhou, a doctoral ...
... Atherosclerosis or buildup of fat in the walls ... older people but it affects a large number of young ... Foundation study. "The proportion of young, apparently healthy adults ... atherosclerosis is staggering," says Dr. Eric Larose, an interventional cardiologist ...
Cached Medicine News:Health News:Sleepy Teens More Prone to Weight Gain: Study 2Health News:IADR/AADR publish study on dental caries vaccine 2Health News:University of Missouri program helps teachers prevent teen suicides 2Health News:University of Missouri program helps teachers prevent teen suicides 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 2Health News:Close-up on endometriosis at 40th AAGL Global Congress 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 4Health News:Drinking More Fluids Could Lower Men's Bladder Cancer Risk 2Health News:Young, apparently healthy -- and at risk of heart disease 2Health News:Young, apparently healthy -- and at risk of heart disease 3
The RU is a low profile implantable bipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
The RZ is a small lead body profile implantable unipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
... The Vitatron Crystalline lead series ... designed for optimal sensing performance ... the sensing of far-field R ... leads allow a higher sensitivity ...
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
Medicine Products: